Author details

Full Name

Kylie L Gorringe

Affiliation

ORCID

Career Start Year

1998

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37406453	TP53 as a Diagnostic Aid in the Distinction of Ovarian Mucinous Borderline Tumors From Mucinous Carcinoma.	Int J Gynecol Pathol	2024
36603894	Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials.		2023
37277207	Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.		2023
37208678	Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.	BMC Cancer	2023
36482277	Identifying recurrences and metastasis after ductal carcinoma inâ¿¿situ (DCIS) of the breast.		2023
35109903	Evaluating statistical approaches to define clonal origin of tumours using bulk DNA sequencing: context is everything.		2022
35768582	Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.	NPJ Precis Oncol	2022
36222710	Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.	Clin Cancer Res	2022
35533650	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.	Pathobiology	2022
34897700	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.	J Pathol	2022
34830751	The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic.	Cancers	2021
34117267	Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study.	npj Breast Cancer	2021
33774196	Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett's Esophagus.	Cellular and Molecular Gastroenterology and Hepatology	2021
33980861	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects.	NPJ Breast Cancer	2021
33151585	Primary mucinous ovarian neoplasms rarely show germ cell histogenesis.	Histopathology	2021
32901952	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.	J Pathol	2021
34773517	Options for the Treatment of Mucinous Ovarian Carcinoma.	Current Treatment Options in Oncology	2021
31444238	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.	Journal of Clinical Pathology	2020
32203210	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.	British Journal of Cancer	2020
32357859	Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei.	BMC Cancer	2020
32242007	Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes.	Nature Communications	2020
32698852	Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours.	BMC Res Notes	2020
31239549	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.	Mod Pathol	2019
30429518	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.	Modern Pathology	2019
31175327	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.	Modern Pathology	2019
31175326	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.	Modern Pathology	2019
30746706	Molecular comparison of interval and screen-detected breast cancers.	Journal of Pathology	2019
31065110	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.	British Journal of Cancer	2019
30949688	Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.	J Natl Cancer Inst	2019
30843206	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma.	J Pathol	2019
30725481	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma inÂ situ.	Histopathology	2019
29316957	Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.	Breast Cancer Research	2018
29955142	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.	Mod Pathol	2018
30627526	When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy.	Frontiers in Oncology	2018
30410060	Prolyl-4-hydroxylase Î¿ subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).	British Journal of Cancer	2018
30224651	Mutations in RECQL are not associated with breast cancer risk in an Australian population.	Nature Genetics	2018
29720474	Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.	Dis Model Mech	2018
29720211	Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape.	Breast Cancer Research	2018
29431189	Molecular analysis of PALB2-associated breast cancers.	Journal of Pathology	2018
29633055	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.	Breast Cancer Research and Treatment	2018
29197112	Invasion in breast lesions: the role of the epithelial-stroma barrier.	Histopathology	2018
28081715	Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.	Genome Med	2017
28338653	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.	Mod Pathol	2017
28451966	Phenotypic characterisation of breast cancer: the role of CDC42.	Breast Cancer Research and Treatment	2017
28451459	Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma.	Journal of Pathology: Clinical Research	2017
28611201	Relationship of the Breast Ductal Carcinoma <i>In Situ</i> Immune Microenvironment with Clinicopathological and Genetic Features.	Clin Cancer Res	2017
29137369	LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness.	Oncotarget	2017
29109942	Ductal Carcinoma Biology, Biomarkers, and Diagnosis.	Frontiers in Oncology	2017
27846907	Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue.	Genome Medicine	2016
26990228	Reply to the Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast.	Histopathology	2016